| 殷 娜,孙秀丽,吴红梅,侯国存,高宏艳.前列地尔联合尿毒清颗粒对慢性肾衰竭患者血清甲状旁腺激素、同型半胱氨酸水平及临床疗效的影响[J].现代生物医学进展英文版,2017,17(10):1945-1948. |
| 前列地尔联合尿毒清颗粒对慢性肾衰竭患者血清甲状旁腺激素、同型半胱氨酸水平及临床疗效的影响 |
| Effects of Alprostadil combined with Uremic Clearance Granule on Serum Parathyroid Hormone and Homocysteine Levels in Patients with Chronic Renal Failure and Its Clinical Efficacy |
| Received:September 09, 2016 Revised:September 26, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.10.039 |
| 中文关键词: 前列地尔 尿毒清颗粒 慢性肾衰竭患者 甲状旁腺激素 同型半胱氨酸 |
| 英文关键词: Alprostadil Uremic clearance granule Chronic renal failure Parathyroid hormone Homocysteine |
| 基金项目:内蒙古自治区自然科学基金项目(20040701093) |
|
| Hits: 468 |
| Download times: 268 |
| 中文摘要: |
| 摘要 目的：探究前列地尔联合尿毒清颗粒对慢性肾衰竭患者血清甲状旁腺激素、同型半胱氨酸及临床疗效的影响。方法：收集我院收治的慢性肾衰竭患者74例，根据随机对照表分为对照组和试验组，每组37例。对照组予以前列地尔注射液治疗，试验组在对照组基础上予以尿毒清颗粒治疗。观察并比较两组患者临床疗效，治疗前后血清肌酐(SCr)、尿素氮(BUN)、血尿酸(UA)、内生肌酐清除率(Ccr)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、甲状旁腺素(PTH)、β2微球蛋白(β2-MG)水平以及不良反应的发生情况。结果：与对照组相比，试验组治疗后临床总有效率较高(P＜0.05)。两组治疗后血清肌酐、尿素氮、血尿酸水平下降(P＜0.05)，内生肌酐清除率水平升高(P＜0.05)；与对照组相比，试验组血清肌酐、尿素氮、血尿酸水平较低(P＜0.05)，内生肌酐清除率水平较高(P＜0.05)。两组治疗后超敏C反应蛋白、同型半胱氨酸、甲状旁腺素以及?茁2微球蛋白水平降低(P＜0.05)；与对照组相比，试验组超敏C反应蛋白、同型半胱氨酸、甲状旁腺素以及β2微球蛋白水平较低(P＜0.05)。两组不良反应发生情况相比差异无统计学意义(P＞0.05)。结论：前列地尔联合尿毒清颗粒对慢性肾衰竭患者的临床疗效显著，安全性较高，可能与其下调血清甲状旁腺激素以、同型半胱氨酸及β2微球蛋白水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of alprostadil combined with uremic clearance granule on the serum levels of parathyroid hormone and homocysteine in patients with chronic renal failure and its clinical efficacy. Methods: 74 patients with chronic renal failure who were treated in our hospital were selected and randomly divided into the experiment group and control group with 37 cases in each group. The patients in the control group were treated with alprostadil injection, while the patients in the experiment group were treated with uremic clearance granule on the basis of the control group. The clinical efficacy and the serum levels of creatinine (SCr), blood urea nitrogen (BUN), uric acid (UA), endogenous creatinine clearance rate (Ccr), hypersensitive c-reactive protein (hs- CRP), homocysteine (Hcy), parathyroid hormone (PTH) and p2 microglobulin (p2 - MG) and adverse reactions were observed and compared between the two groups before and after the treatment. Results: Compared with the control group, the clinical total effective rate of the experiment group was higher (P<0.05). Compared with before treatment, the serum levels of creatinine, blood urea nitrogen and uric acid of the two groups decreased, while the endogenous creatinine clearance rate increased after the treatment (P<0.05); Compared with the control group, the serum levels of creatinine, blood urea nitrogen and uric acid in the experiment group were lower, and the endogenous creatinine clearance rate was higher (P<0.05). Compared with before treatment, the serum levels of hypersensitive C-reactive protein, homocysteine, parathyroid hormone and p2 microglobulin in the two groups decreased after the treatment (P<0.05); Compared with the control group, the serum levels of hypersensitive C-reactive protein, homocysteine, parathyroid hormone and p2 microglobulin in the experiment group were lower (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Alprostadil combined with uremic clearance granule could reduce the serum levels of parathyroid hormone and homocysteine with high safety in the treatment of patients with chronic renal failure. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
